Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP439395.RAZo6y658hM1o_k_89lOXcJ81QtE7QxZo6XG8Lz8Y1Xf8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP439395.RAZo6y658hM1o_k_89lOXcJ81QtE7QxZo6XG8Lz8Y1Xf8130_assertion type Assertion NP439395.RAZo6y658hM1o_k_89lOXcJ81QtE7QxZo6XG8Lz8Y1Xf8130_head.
- NP439395.RAZo6y658hM1o_k_89lOXcJ81QtE7QxZo6XG8Lz8Y1Xf8130_assertion description "[Our study demonstrated that SLE patients carrying the genotypes with GSTP1 codon 105 mutation [GSTP1*-105I/V (heterozygote) and GSTP1*-105 V/V (homozygote)] had an increased risk of myelotoxicity when treated with pulsed high-dose CTX therapy (Odds ratio (OR) 5.00, 95% confidence interval (CI) 1.96, 12.76); especially in patients younger than 30 years (OR 7.50, 95% CI 2.14, 26.24), or in patients treated with a total CTX dose greater than 1.0 g (OR 12.88, 95% CI 3.16, 52.57).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP439395.RAZo6y658hM1o_k_89lOXcJ81QtE7QxZo6XG8Lz8Y1Xf8130_provenance.
- NP439395.RAZo6y658hM1o_k_89lOXcJ81QtE7QxZo6XG8Lz8Y1Xf8130_assertion evidence source_evidence_literature NP439395.RAZo6y658hM1o_k_89lOXcJ81QtE7QxZo6XG8Lz8Y1Xf8130_provenance.
- NP439395.RAZo6y658hM1o_k_89lOXcJ81QtE7QxZo6XG8Lz8Y1Xf8130_assertion SIO_000772 16995867 NP439395.RAZo6y658hM1o_k_89lOXcJ81QtE7QxZo6XG8Lz8Y1Xf8130_provenance.
- NP439395.RAZo6y658hM1o_k_89lOXcJ81QtE7QxZo6XG8Lz8Y1Xf8130_assertion wasDerivedFrom befree-20150227 NP439395.RAZo6y658hM1o_k_89lOXcJ81QtE7QxZo6XG8Lz8Y1Xf8130_provenance.
- NP439395.RAZo6y658hM1o_k_89lOXcJ81QtE7QxZo6XG8Lz8Y1Xf8130_assertion wasGeneratedBy ECO_0000203 NP439395.RAZo6y658hM1o_k_89lOXcJ81QtE7QxZo6XG8Lz8Y1Xf8130_provenance.